BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD. REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 7, 2024, 7:00 CEST – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of the transparency notificat...
BioSenic S.A. : Notification de transparence reçue de la part de ABO Infinium Americas OpCo LTD. INFORMATION REGLEMENTEE Article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes Mont-Saint-Guibert, Belgique, le 7 octobre 2024 à 7h00 CEST – (Euronext Bruxelles et Paris: BIOS), société spécialisée en essais cliniques dans les maladies auto-immunes et inflammatoires graves et la thérapie cellulaire, annonce aujourd’hui la réception de la notification de transparence de ABO Infinium Americas OpCo LTD. Les détails de la notification de transparence sont rep...
We maintain a defensive stance on the market for 2H24. The long anticipated expectations for interest rate cuts by central banks will finally come to pass. The election fever in the US is reaching boiling point and the conversations are becoming more polarised than before. Also corporate profit growth in Europe slows and the French elections have cast a negative spell. In Germany by-elections in the Eastern part showed a shift to extreme right and left that will make budget decisions even more ...
BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors PRIVILEGED INFORMATION Biosenic and Global Tech Opportunities 15 ("GTO 15") have entered into an amendment to the convertible bonds ("CB") agreement securing a further EUR 1.5 million of the programme, including at least two tranches of EUR 0.2 million net each.François Rieger and Véronique Pomi-Schneiter resign from their positions as CEO, chairman and executi...
BioSenic reports half year 2024 results REGULATED INFORMATIONThe interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section ‘Financial reports'. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report, the original French version will prevail. Mont-Saint...
BioSenic publie ses résultats pour le premier semestre 2024 INFORMATION REGLEMENTEELe rapport semestriel est préparé conformément à l’article 13 de l’Arrêté Royal relatif aux obligations des émetteurs d’instruments financiers admis à la négociation sur un marché réglementé et peut être consulté sur le site web de BioSenic dans la section ‘Rapports Financiers’. BioSenic publie son rapport financier semestriel en anglais. Une version en français sera également mise à disposition. Si des différences d’interprétation devaient exister entre les versions anglaise et française de ce rapport, la ve...
Véronique Pomi-Schneiter démissionne de ses fonctions de Directrice Générale Adjointe de BioSenic INFORMATION PRIVILIGIEE Mont-Saint-Guibert, Belgique, le 17 septembre 2024, 7h00 CEST – (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto-immunes et inflammatoires sévères, annonce que Véronique Pomi-Schneiter démissionne pour des raisons personnelles de ses fonctions de Directrice Générale Adjointe de BioSenic. Véronique Pomi-Schneiter contribuera cependant au processus de transition et continuera à siéger en tant qu'administrateur non-...
Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, September 17, 2024 7.00pm CEST – (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, today announces that Véronique Pomi-Schneiter resignes for personal reasons as Deputy CEO of BioSenic. Véronique Pomi-Schneiter will fully assist in the transition process and continue to serve as non-executive member of the board of directors of BioSenic, as well as an executive member of the board of directors (i.e., t...
We reiterate our BUY and increase our target price from €15 to €16 following Recticel's 1H24 results, to reflect a lower WACC and broadly stable estimates. We remain convinced by the medium-to-long term potential of the Insulation market - this should provide Recticel with ample room to grow organically and, thanks to its net cash position, through M&A. We view future acquisitions as a key catalyst for the share price over the short term, as these would confirm the ambition of the group to mater...
1M Performance - Absolute: During July'24 (1M period), the KBCS Holdings Universe posted a return of 0.5% which was mainly driven by multi-asset holdings (+1.7%) while single-asset holdings posted a negative return of -1.3%. The 3 top performers during the period were HAL Trust (+5.1%), Texaf (+2.9%), and The Infrastructure Company (TINC, +9.6%) while the 3 worst performers were Brederode (-2.8%), Solvac (-5.3%), and Whitestone Group (-7.2%). YTD Performance - Relative: On a YTD basis (as of A...
ING Benelux Conference London: Aalberts, Arcadis, Azelis, Barco, Basic-Fit, Brunel International, DEME Group, Euronext, Fagron, Heijmans, Kinepolis, Lotus Bakeries, Melexis, Ontex, Randstad, Recticel, SBM Offshore, TKH Group, Van Lanschot Kempen Other company stories - OCI: Divestment of Methanol to Methanex for US$2.05bn, Staffing: US August temp volumes marginally better trend; NFP jobs miss
In this September update of our Dynamic Top Pick List we make 4 changes. •We include Cofinimmo in our Dynamic Top Pick List after our recent upgrade from Accumulate to Buy. We expect the name to outperform in a decreasing interest rate environment given its relatively high leverage and cheap valuation. We also believe the risk of a dilutive equity raise eased when the FY24 capex decreased from € 320m to € 250m. The management stays disciplined in its capex program and continues to focus on asse...
We updated our model on Van de Velde after the unfavourable weather conditions led to lower 1H24 sales in many stores. Especially in swim sales, they experienced a decrease. We lower our Target Price to € 38.5 (was € 40) but maintain our Buy-rating as Van de Velde approaches 2H24 with confidence, even though they remain vigilant in the current environment. The strong market position of its brands PrimaDonna and Marie Jo in both the Benelux and Germany provides them with a strong foundation for ...
We have finetuned our earnings model post the 1H24 results release, with adjusted EBITDA forecasts for FY24-26 lowered by between 2% and 5%, reflecting the competitive landscape (mainly in the Boards business). Despite the reduced forecasts, we still expect Recticel to grow adjusted EBITDA by c. 31% in FY24 and by 19% in FY25, benefiting from savings initiatives and the Rex integration & growth. Building markets are bottoming out, but we do not expect meaningful improvement in momentum until 202...
Below are the highlights from the 1H results conference call. On the back of double digit underlying volume growth, 1H Adj EBITDA jumped by 38% to € 25.1m, which was roughly in line with our forecast and c 3m above consensus. Although Recticel expects to have seen the market bottom in Western Europe whilst noting an improvement in the UK, FY guidance of around € 50m adjusted EBITDA is slightly below our and consensus forecasts of respectively € 52m and € 54m. Although we do believe in the longer...
>Strong core versus weak non-core results - H1 results up 17%. AvH has improved its 24H1 reported net result by 17% y-o-y to € 200.4m (AAOB € 218m post results listed subsidiaries), equivalent to an EPS of € 6.13 per share, and up from € 5.16 per share in 23H1. Key drivers: DEME and Private Banking. The Contribution from AvH’s core segments rose by 50% to € 224.2m (AAOB € 215.0m post results listed subsidiaries), with DEME yesterday clearly beating all analyst e...
Ackermans & van Haaren: Indian participation casts shadow over excellent result of core segments. ASML: Spotlight on export restrictions again. Basic-Fit: Dutch parliament persists in plans to raise VAT for oa Sports to 21%. CFE: Earnings quality improved in challenging markets. Eurocommercial Properties: Better numbers, guidance moved toward the higher end of the range. OCI: IFCO sale successfully closed, cash return unlocked Recticel: Solid 1H24 beat, FY guidance may disappoint. SIF Grou...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.